Whereas the degree of concordance between HER2 amplification by NGS and HER2 protein overexpression by IHC is generally high (>90%) [31], it varies by tumor type [32], and approximately 30% discordance occurs between baseline and subsequent tumor testing [32]. Here, ERBB2 is linked to neoplasm.